Related Experiment Video
Updated: Jul 7, 2026
11:15
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
hSNF5 /INI1 mutation analysis in acute myeloid leukemia
Yu-Chieh Su1, Chao-Bin Chen2, Ya-Ting Chang2
1Division of Hematology-Oncology, Department of Internal Medicine, Buddhist Dalin TzuChi General Hospital, No. 2, Ming-Shen Road, Chiayi County, Taiwan. hepatoma@ms3.hinet.net.
International Journal of Hematology
|February 13, 2008
Summary
The human immunodeficiency virus integrase interactor 1 (hSNF5/INI1) gene, located in chromosome 22q11.2, was analyzed for its role in acute myeloid leukemia (AML). This study found no significant mutations, suggesting hSNF5/INI1 is not a key factor in AML development.
Area of Science:
- Genetics
- Oncology
- Molecular Biology
Background:
- The 22q11.2 chromosomal region, containing the hSNF5/INI1 gene, is implicated as a potential tumor suppressor locus.
- Deletions in this region are frequently observed in aggressive pediatric cancers.
Purpose of the Study:
- To investigate the potential involvement of the hSNF5/INI1 gene in leukemogenesis.
- To determine if mutations in hSNF5/INI1 are associated with acute myeloid leukemia (AML).
Main Methods:
- Mutation analysis of the hSNF5/INI1 gene was conducted.
- The study utilized 5 hematopoietic cell lines, AML specimens, and normal controls.
Main Results:
- Two single nucleotide polymorphisms (SNPs) were identified in exon 4 and exon 9 of the hSNF5/INI1 gene.
- No other significant mutations were detected in the analyzed samples.
Conclusions:
- The hSNF5/INI1 gene does not appear to play a significant role in the leukemogenesis of acute myeloid leukemia (AML).
- Further research may be needed to explore other genetic factors in AML development.
